batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Three more Pfizer oncology projects go in latest cull 1 November 2023 Sting’s fortunes wax and wane 1 November 2023 Pfizer enters phase 3 with a CDK4 inhibitor 31 October 2023 Teneobio falls short of Amgen’s expectations 31 October 2023 Loqtorzi becomes ninth US anti-PD-(L)1 drug 30 October 2023 Deciphera sets sights on a second marketed drug 30 October 2023 AstraZeneca goes early with new datopotamab breast phase 3s 26 October 2023 ESMO 2023 – how datopotamab's lung side effects are graded 24 October 2023 Load More